StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3056% above fair value
$30.52+0.57 (+1.90%)

Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%

Pfizer Inflectra / Remsima (infliximab biosimilar) by Year

Inflectra / Remsima (infliximab biosimilar) — U.S. revenues ($M) ($M)

QuarterlyAnnual

Pfizer Inflectra / Remsima (infliximab biosimilar): $511M in FY2025, up 90.7% from a year earlier. That is the highest of the 10 years on record here.

Latest, FY2025
511
Period ended Dec 31, 2025
Change on a year earlier
+90.7%
268 in FY2024
History
10 years
Since FY2016
Sources
9
Documents cited below

Where the FY2025 figure comes from

“|| Inflectra | 646 | 509 | 27% | 27% | 511 | 268 | 91% | 134 | 241 | (44%) | (43%)”

Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗

Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedInflectra / Remsima (infliximab biosimilar) — U.S. revenues ($M) ($M)Year on yearSource
FY2025Dec 31, 2025511+90.7%Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
FY2024Dec 31, 2024268+4.3%Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
FY2023Dec 31, 2023257+129.5%Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗
FY2022Dec 31, 2022112+49.3%Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗
FY2021Dec 31, 202175+29.3%Form 8-K (Earnings / Guidance Release) (pfe-12312022xex99.htm, filed 2023-01-31) ↗
FY2020Dec 31, 202058+81.3%Form 8-K (Earnings / Guidance Release) (pfe-12312021xex99.htm, filed 2022-02-08) ↗
FY2019Dec 31, 201932+33.3%Form 8-K (Earnings / Guidance Release) (pfe-12312020xex99.htm, filed 2021-02-02) ↗
FY2018Dec 31, 201824-79.7%Form 8-K (Earnings / Guidance Release) (pfe-12312019xex99.htm, filed 2020-01-28) ↗
FY2017Dec 31, 2017118+2,850.0%Form 8-K (Earnings / Guidance Release) (pfe-12312018xex99.htm, filed 2019-01-29) ↗
FY2016Dec 31, 20164–Form 8-K (Earnings / Guidance Release) (pfe-12312017xex99.htm, filed 2018-01-30) ↗

Breakdown

What makes up inflectra / Remsima (infliximab biosimilar)

Cite this data

StockData. (2026). Pfizer Inflectra / Remsima (infliximab biosimilar) ($M), annual FY2016–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/inflectra-us

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.